Clinical Study on Xiaoaiping Oral Liquid Combined with Bevacizumab in Treatment of Advanced Non-small Cell Lung Cancer

Abstract

Objective. To study the clinical efficacy of Xiaoaiping Oral Liquid combined with Bevacizumab Injection in treatment of advanced non-small cell lung cancer. Methods. Patients (128 cases) with advanced non-small cell lung cancer in the First Affiliated Hospital of Henan University from January 2016 to January 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients were treated with TC regimen (carboplatin + paclitaxel). Patients in the control group were iv administered with Bevacizumab Injection at the first day, 7.5 mg/kg. Patients in the treatment group were po administered with Xiaoaiping Oral Liquid on the basis of the control group, 10 mL/time, three times daily. A course had 21 days, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and serum levels of CEA, NSE, and CA125, KPS score, progression-free survival time (PFS), total survival time (OS), and adverse reactions were compared between two groups. Results. After treatment, DCR (78.12% vs 67.19%) and ORR (64.06% vs 51.56%) in the treatment group were significantly higher than those in the control group ( P < 0.05). After treatment, the serum levels of CEA, NSE and CA125 in the two groups were significantly reduced ( P < 0.05). And the tumor markers in the treatment group were significantly lower than those in the control group ( P < 0.05). After treatment, KPS scores in two groups were significantly decreased ( P < 0.05), and the KPS score in the treatment group was significantly lower than that in the control group ( P < 0.05). After treatment, PFS and OS in the treatment group were significantly higher than those in the control group ( P < 0.05). The incidence of gastrointestinal reaction, thrombocytopenia, leukopenia and liver dysfunction in the treatment group was significantly lower than that in the control group ( P < 0.05). Conclusion. Xiaoaiping Oral Liquid combined with Bevacizumab Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life of patients and reduce the serum levels of tumor markers, which is worthy of clinical application.